Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
candsartan cilexetil · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| candsartan cilexetil | DRUG | - |
Inclusion Criteria: * The subjects must have fulfilled the eligibility criteria for and have participated in Study 261A or did not participate in Study 261A but meet the following criteria: * Diagnosed and untreated hypertension, or * Diagnosed and treated, but off antihypertensive treatment for at...
Candesartan cilexetil is used for hypertension and pediatric hypertension. It is an investigational small molecule in Phase 3 development for these cardiovascular conditions. The drug is being studied in pediatric subjects aged 6 to less than 17 years with hypertension.
Candesartan cilexetil is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials to evaluate the drug's efficacy, safety, and pharmacokinetics in pediatric patients with hypertension.
Candesartan cilexetil is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for hypertension and pediatric hypertension. Two Phase 3 trials have been completed as part of its development program.
Candesartan cilexetil has been studied in two completed Phase 3 trials: NCT00244595, which evaluated efficacy, safety, and pharmacokinetics in hypertensive pediatric subjects aged 6 to less than 17 years, and NCT00244634, a dose range finding study in pediatric subjects with hypertension.
Yes, candesartan cilexetil is the same as Atacand. One of its clinical trials, NCT00244634, is titled 'Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age,' confirming that Atacand is a brand name for candesartan cilexetil.